Last reviewed · How we verify
PET MPI
PET MPI is a myocardial perfusion imaging agent that uses a radioactive tracer to visualize blood flow to the heart muscle during stress and rest conditions.
PET MPI is a myocardial perfusion imaging agent that uses a radioactive tracer to visualize blood flow to the heart muscle during stress and rest conditions. Used for Myocardial perfusion imaging for detection and assessment of coronary artery disease, Evaluation of myocardial viability in patients with prior myocardial infarction.
At a glance
| Generic name | PET MPI |
|---|---|
| Sponsor | GE Healthcare |
| Drug class | Radiopharmaceutical diagnostic agent |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
PET MPI (Positron Emission Tomography Myocardial Perfusion Imaging) employs a positron-emitting radiopharmaceutical to assess coronary artery perfusion and myocardial viability. The tracer accumulates in areas of adequate blood flow, allowing clinicians to identify regions of ischemia or infarction. This diagnostic imaging approach helps stratify cardiac risk and guide treatment decisions in patients with suspected or known coronary artery disease.
Approved indications
- Myocardial perfusion imaging for detection and assessment of coronary artery disease
- Evaluation of myocardial viability in patients with prior myocardial infarction
Common side effects
- Radiation exposure
- Stress-induced symptoms (chest discomfort, dyspnea, arrhythmia)
Key clinical trials
- Safety of PET MPI Using the CRCHUM N-13 Ammonia (PHASE4)
- Comparison of Diagnostic Accuracy Between XTR004 PET MPI and the Composite Index of Quantitative Coronary Angiography (QCA) and Fractional Flow Reserve (FFR) (PHASE3)
- Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy
- RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evaluate Responses of Myocardial FLOW (RAPID-WATER-FLOW) (PHASE3)
- Comparative Imaging of XTR004 PET and MIBI SPECT in Borderline Coronary Stenosis (PHASE2)
- Myocardial Perfusion Imaging Galmydar Rest/Stress (EARLY_PHASE1)
- The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI (NA)
- PET-MRI of Reward System in Parkinson's Disease With RBD (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PET MPI CI brief — competitive landscape report
- PET MPI updates RSS · CI watch RSS
- GE Healthcare portfolio CI